Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Teva Pharmaceutical Industries (TEVA) and raises the price target from $15 to $17.
February 05, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Teva Pharmaceutical Industries and raises the price target from $15 to $17.
The upgrade in price target by a reputable analyst like Balaji Prasad from Barclays indicates a strong confidence in Teva Pharmaceutical Industries' future performance. This is likely to be viewed positively by the market, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100